ALRT Health-E-Connect Diabetes Management System Used in Clinical Trial to Determine Adherence of Prescribed Self-Testing of Blood Sugar and Its Effects on Type 2 Diabetes

Richmond, Virginia, UNITED STATES

ATLANTA GA--(Marketwire - January 12, 2009) - ALR Technologies Inc. (OTCBB: ALRT) announces the funding for a clinical trial (the Trial) sponsored by Endocrine Research Society (ERS) of Vancouver, Canada. The objective of this trial is to determine the effectiveness of ALRT's diabetes compliance system vs. standard regimen on increasing patient compliance with prescribed self-testing of blood sugar in Type 2 diabetics.

Currently, industry data indicates that only 14% of prescribed self-testing of blood sugar is actually performed. Results from a pilot project reported by ALRT in 2008 showed self-testing increased from 1.4 times per day to 3.1 times per day and A1c decreased from 7.6 to 6.7


Adherent self-testing of blood sugar as prescribed is necessary for effective self-management of diabetes by patients. Effective self-management lowers A1c levels and will improve containment of complications due to diabetes.

Patients in the Trial will be using ALRT's Health-E-Connect web based communication system to upload their time stamped blood sugar data direct from glucometers. The data is securely reported to designated health professionals for review. Adjustments to therapies as required in between visits to the clinic can be efficiently dispensed by authorized health professionals.

Abbott Diabetes Care is providing diabetes testing supplies for the Trial.

Details of the trial are available at:

About ERS, Endocrine Research Society, Vancouver, Canada

The Society conducts research on new drugs and procedures. It organizes an annual diabetes directors' seminar (a conference for the medical directors of diabetes centers of B.C.), the annual Bill Vlahos Memorial Lecture and annual B.C. Endocrine Days (a conference on Endocrinology for general practitioners) and Annual Kelowna Endocrine Days (A conference on Endocrinology for specialists). The Society maintains a database to evaluate patient outcomes. Additional information on ERS or the clinical trial contact: Adel Mazanderani at 604-602-1011; email:

About ALR Technologies Inc.

The ALRT Health-E-Connect Disease Management System is designed to enhance compliance of prescribed therapies and report diagnostic data from a number of devices to health professionals for monitoring of patients. The System facilitates cost effective continued oversight of patients by authorized health professionals in between visits to the clinic. More information on ALR Technologies and its products can be found at Public Relations: 678-881-0002 Ext. 704 e-mail:

This release contains certain "forward-looking statements" relating to ALR Technologies' business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words "estimate," "expect," "anticipate," "believe" and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company's quarterly filings with the Securities Exchange Commission.

Contact Information: Public Relations: 678-881-0002 Ext. 704 e-mail: